Literature DB >> 17636537

Does 18fluoro-fluorodeoxyglucose positron emission tomography improve recurrence detection in patients treated for head and neck squamous cell carcinoma with negative clinical follow-up?

Pierre Y Salaun1, Ronan Abgral, Solène Querellou, Olivier Couturier, Gérald Valette, Yves Bizais, Françoise Kraeber-Bodéré.   

Abstract

BACKGROUND: The aim of this study was to determine the benefits of 18fluoro-fluorodeoxyglucose positron emission tomography (18F-FDG PET) in the detection of head and neck squamous cell carcinoma (HNSCC) recurrence in patients with negative clinical follow-up.
METHODS: Whole-body 18FDG-PET was performed in 30 patients treated for HNSCC without any clinical element for recurrence.
RESULTS: Twenty-one negative PET and 9 positive results were seen. One patient with abnormal 18F-FDG uptake in the laryngeal area did not have recurrent HNSCC (false positive). Eight had proven recurrence. The sensitivity and specificity of 18F-FDG PET for the diagnosis of HNSCC recurrence were 100% (8/8) and 95% (21/22), respectively. The positive predictive value was 89% (8/9). The negative predictive value was 100% (21/21). The overall accuracy was 97% (29/30).
CONCLUSION: The results of our study confirm the high effectiveness of 18F-FDG PET in assessment of HNSCC recurrence and suggest that it is more accurate than conventional physical examination follow-up alone.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17636537     DOI: 10.1002/hed.20645

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  13 in total

Review 1.  Present and future role of FDG-PET/CT imaging in the management of head and neck carcinoma.

Authors:  Kazuhiro Kitajima; Yuko Suenaga; Kazuro Sugimura
Journal:  Jpn J Radiol       Date:  2015-10-27       Impact factor: 2.374

2.  Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis.

Authors:  Tejpal Gupta; Zubin Master; Sadhana Kannan; Jai Prakash Agarwal; Sarbani Ghsoh-Laskar; Venkatesh Rangarajan; Vedang Murthy; Ashwini Budrukkar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-08-19       Impact factor: 9.236

3.  FDG-PET/contrast-enhanced CT as a post-treatment tool in head and neck squamous cell carcinoma: comparison with FDG-PET/non-contrast-enhanced CT and contrast-enhanced CT.

Authors:  Yuko Suenaga; Kazuhiro Kitajima; Takeaki Ishihara; Ryohei Sasaki; Naoki Otsuki; Ken-Ichi Nibu; Tsutomu Minamikawa; Naomi Kiyota; Kazuro Sugimura
Journal:  Eur Radiol       Date:  2015-07-19       Impact factor: 5.315

4.  Diagnostic performance of FDG PET/CT to detect subclinical HNSCC recurrence 6 months after the end of treatment.

Authors:  Philippe Robin; Ronan Abgral; Gérald Valette; Pierre-Yves Le Roux; Nathalie Keromnes; Jean Rousset; Gaël Potard; Xavier Palard; Rémi Marianowski; Pierre-Yves Salaun
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-08-29       Impact factor: 9.236

Review 5.  (18)F-FDG PET/CT quantification in head and neck squamous cell cancer: principles, technical issues and clinical applications.

Authors:  Gianpiero Manca; Eleonora Vanzi; Domenico Rubello; Francesco Giammarile; Gaia Grassetto; Ka Kit Wong; Alan C Perkins; Patrick M Colletti; Duccio Volterrani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-01-19       Impact factor: 9.236

6.  Perceived value drives use of routine asymptomatic surveillance PET/CT by physicians who treat head and neck cancer.

Authors:  Benjamin R Roman; Shivangi Lohia; Nandita Mitra; Marilene B Wang; Anna M Pou; F Christopher Holsinger; David Myssiorek; David Goldenberg; David A Asch; Judy A Shea
Journal:  Head Neck       Date:  2020-01-10       Impact factor: 3.147

7.  Evaluating the potential role of PET/CT in the posttreatment surveillance of head and neck cancer.

Authors:  Shrujal S Baxi; Lara Dunn; David G Pfister
Journal:  J Natl Compr Canc Netw       Date:  2015-03       Impact factor: 11.908

8.  Prognostic value of volumetric parameters measured by 18F-FDG PET/CT in patients with head and neck squamous cell carcinoma.

Authors:  Ronan Abgral; Nathalie Keromnes; Philippe Robin; Pierre-Yves Le Roux; David Bourhis; Xavier Palard; Jean Rousset; Gérald Valette; Rémi Marianowski; Pierre-Yves Salaün
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-11-07       Impact factor: 9.236

9.  The lack of evidence for PET or PET/CT surveillance of patients with treated lymphoma, colorectal cancer, and head and neck cancer: a systematic review.

Authors:  Kamal Patel; Nira Hadar; Jounghee Lee; Barry A Siegel; Bruce E Hillner; Joseph Lau
Journal:  J Nucl Med       Date:  2013-06-17       Impact factor: 10.057

10.  Clinical Applications of FDG PET and PET/CT in Head and Neck Cancer.

Authors:  Akram Al-Ibraheem; Andreas Buck; Bernd Joachim Krause; Klemens Scheidhauer; Markus Schwaiger
Journal:  J Oncol       Date:  2009-08-20       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.